Member
of the board of directors of Charles River Laboratories
International, Inc.
Member of the board of directors of
SpringWorks Therapeutics, Inc.
President of global research and development at AstraZeneca
plc., 2010-2013.
President and senior vice president within
Research and Development, and other roles, Pfizer, Inc.,
1995-2010.
Visiting professor at the Department of Pharmacy
at King’s College, London, 1998-2006 and at the Department of
Biomedical Sciences at the University of Lincoln, 1998-2014.
Considered independent under the Danish Corporate Governance
Recommendations.
Member of the Board of Directors since March
2018. Most recently elected in 2024 for a term of one year.
Chair of the Research & Development Committee since March
2018.
Member of the Remuneration Committee since March
2021.
Global corporate leadership.
Healthcare and pharma
industry.
Medicine & science.
Technology, data
& digital.
Business development, M&A and external
innovation sourcing.
Human capital management.
1984: Doctorate/PhD, University of Edinburgh, UK.
1979: BSc (First Class Honours) in Microbiology, Heriot-Watt
University, Edinburgh, UK.